Allowed claims in 09/396,523

~~ATTACHMENT 1~~

~~Claims on Appeal:~~

1

~~3~~. A N^1-monosubstituted polyamine analogue or derivative represented by the formula

$$R\text{-}CO\text{-}NH\text{-}(CH_2)_3\text{-}NH\text{-}(CH_2)_4\text{-}NH\text{-}(CH_2)_3\text{-}NH_2$$

wherein R is selected from a D or L amino acid; D or L ornithine, an alicyclic, a single or multi-ring aromatic; aliphatic-substituted single or multi-ring aromatic; and a substituted or unsubstituted, single or multi-ring heterocyclic and

Insert 10/13/2005

wherein said analogue or derivative does not have a formula represented by ID 1022, 1043, or 1202.

2 1

~~33~~. An analogue or derivative according to claim ~~3~~ wherein R is a D or L amino acid or D or L ornithine.

3

~~34~~. A composition comprising a polyamine analogue or derivative according to claim ~~3, 32~~ or ~~33~~ and a pharmaceutically acceptable excipient.

4

~~35~~. A composition comprising a polyamine analogue or derivative according to claim 3, a pharmaceutically acceptable excipient, and an inhibitor of polyamine synthesis.

5 4

~~36~~. A composition according to claim ~~35~~ wherein said inhibitor of polyamine synthesis is difluoromethylornithine (DFMO).

6

~~37~~. A method for treating a disease or a condition in a subject associated with undesired cell proliferation and/or which is treatable by inhibition of polyamine transport, comprising administering to said subject a polyamine analogue or derivative according to claim ~~3~~.

7 6

~~38~~. A method according to claim ~~37~~ wherein said undesired cell proliferation is associated with proliferation of cells of the immune system, cells of the vascular neontima, tumor cells or with undesired angiogenesis.

8 6

~~39~~. A method according to claim ~~37~~ wherein said disease or condition is cancer or post-angioplasty injury.

9 6

~~40~~. A method according to claim ~~37~~ further comprising administration of an inhibitor of polyamine synthesis.

41. A method according to claim 40 wherein said inhibitor of polyamine systhesis is difluoromethylornithine (DFMO).

42. A composition according to claim 38 or 39 in solid form

43. A composition according to claim 38 or 39 in liquid form.

44. A method according to any one of claims 37-41 wherein said administering is performed orally, parenterally, topically, transdermally, intravaginally, intranasally, intrabronchially, intracranially, intraocularly, intraaurally, or rectally, or by injection.

45 A method according to claim 44 wherein said administering by injection is intravenous, subcutaneous, intramuscular, intracranial, or intraperitoneal.

47. A composition comprising a polyamine analogue or derivative according to claim 46 and a pharmaceutically acceptable excipient.

48. A method for treating a disease or a condition in a subject comprising administering to said subject a polyamine analogue or derivative according to claim 46.

49. (New) The analogue or derivative of claim 5, wherein said substituted or unsubstituted heterocyclic is a pyrrolidine or a substituted pyrrolidine.

50. (New) The analogue or derivative of claim 49, wherein said substituted pyrrolidine is an N-substituted pyrrolidine.

51. (New) The analogue or derivative of claim 50 represented by the formula ID 1158.

52. (New) The analogue or derivative of claim 3 represented by the formula ID 1224.

53. (New) A method according to claim 37 wherein said condition is associated with cancer.